Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Tax Provisions (2016 - 2025)

ImmunityBio (IBRX) has disclosed Tax Provisions for 10 consecutive years, with -$135000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions changed N/A to -$135000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$135000.0, a N/A change, with the full-year FY2025 number at -$135000.0, changed N/A from a year prior.
  • Tax Provisions was -$135000.0 for Q4 2025 at ImmunityBio, down from -$35000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $269000.0 in Q2 2025 to a low of -$234000.0 in Q1 2025.
  • A 4-year average of -$14666.7 and a median of $1000.0 in 2021 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: surged 3300.0% in 2022, then crashed 217.65% in 2023.
  • ImmunityBio's Tax Provisions stood at $1000.0 in 2021, then soared by 3300.0% to $34000.0 in 2022, then plummeted by 217.65% to -$40000.0 in 2023, then tumbled by 237.5% to -$135000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Tax Provisions are -$135000.0 (Q4 2025), -$35000.0 (Q3 2025), and $269000.0 (Q2 2025).